Loading…
Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL
The feasibility and efficacy of cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B ce...
Saved in:
| Published in: | International journal of hematology 2010-12, Vol.92 (5), p.732-743 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c453t-8dcb0167b6ebd067b0b2170de6fcfe4f9c2bc82f5ebd9d5a9d0a66aea7fc230f3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c453t-8dcb0167b6ebd067b0b2170de6fcfe4f9c2bc82f5ebd9d5a9d0a66aea7fc230f3 |
| container_end_page | 743 |
| container_issue | 5 |
| container_start_page | 732 |
| container_title | International journal of hematology |
| container_volume | 92 |
| creator | Maruyama, Dai Watanabe, Takashi Maeshima, Akiko Miyagi Nomoto, Junko Taniguchi, Hirokazu Azuma, Teruhisa Mori, Masakazu Munakata, Wataru Kim, Sung-Won Kobayashi, Yukio Matsuno, Yoshihiro Tobinai, Kensei |
| description | The feasibility and efficacy of cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL (intermediate DLBCL/BL) have never been reported. The effects of adding rituximab to CODOX-M/IVAC have not been published either. Fifteen consecutive patients with a median age of 39 years were treated with modified CODOX-M/IVAC regimen (particularly, reducing the dose of methotrexate to 3 g/m
2
) with or without rituximab at our institution. Although all patients developed grade 4 neutropenia and grade 3/4 thrombocytopenia/anemia, 93% had febrile neutropenia, 60% showed transaminase elevation, and 40% had mucositis/stomatitis (all grade 3), there were no treatment-related deaths. Two of nine patients treated with rituximab developed biphasic late-onset neutropenia. Thirteen patients (87%) showed complete responses. The remaining two patients had refractory disease; one had presented with peritoneal dissemination and complex chromosomal abnormalities, while the other had double
IGH
–
MYC
and
IGH
–
BCL2
translocations. The estimated 5-year overall and progression-free survival were 87% each, with a median follow-up of 74 months. In conclusion, our modified CODOX-M/IVAC regimen is well tolerated and highly effective in Japanese adult patients with BL and intermediate DLBCL/BL, warranting a larger study for confirmation. |
| doi_str_mv | 10.1007/s12185-010-0728-0 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_816626946</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2207773641</sourcerecordid><originalsourceid>FETCH-LOGICAL-c453t-8dcb0167b6ebd067b0b2170de6fcfe4f9c2bc82f5ebd9d5a9d0a66aea7fc230f3</originalsourceid><addsrcrecordid>eNp1UktvEzEQXhCIhsIP4IIsJKREylJ73zk24VWUKhdA3Faz9rhx2bUX20uTf4-TDa2ExGlszfcYj78oesXoO0ZpeeFYwqo8pozGtEyqmD6OJqwq8jgty-xJNKGLJI_zktGz6Llzt5Sykmbls-gsYSyhRZZNHl1eG6GkQkH4nrem3xrXb6FTAufkt9LcKueVDhdhdsYOjeJKzwloQTr0W-Mt7sAjma427zc_4uvZhZLGyZMAetMbdzweGHzvwUIT5Mj06vvlakb8Fi30e3Kn_JYYe6xm8MQqP-xUBw1RmnyBHjQ6JCCG1pMevELt3UhaDvan8p60-y7M3gGZLtezo9uScGzb-8acDJq34Fx4LTRtGOnIlwh-sOiCkUfboVCH5zTo7xA1CauRQ3Buwd7gv4qjy_pF9FRC6_DlqZ5H3z5--Lr6HK83n65Wl-uYZ3nq40rwhrKibApsBA2VNkn4DoGF5BIzueBJw6tE5qG9EDksBIWiAIRS8iSlMj2P3oy6vTW_BnS-vjWD1cGyrlhRJMUiKwKIjSBujXMWZd3bsEe7rxmtD5mpx8zUITP1ITM1DZzXJ-GhCQu4Z_wNSQC8PQHAcWilBc2Ve8ClZc7KlAVcMuJcaOkbtA8T_t_9D3Xv4Jk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>816626946</pqid></control><display><type>article</type><title>Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL</title><source>Springer Link</source><creator>Maruyama, Dai ; Watanabe, Takashi ; Maeshima, Akiko Miyagi ; Nomoto, Junko ; Taniguchi, Hirokazu ; Azuma, Teruhisa ; Mori, Masakazu ; Munakata, Wataru ; Kim, Sung-Won ; Kobayashi, Yukio ; Matsuno, Yoshihiro ; Tobinai, Kensei</creator><creatorcontrib>Maruyama, Dai ; Watanabe, Takashi ; Maeshima, Akiko Miyagi ; Nomoto, Junko ; Taniguchi, Hirokazu ; Azuma, Teruhisa ; Mori, Masakazu ; Munakata, Wataru ; Kim, Sung-Won ; Kobayashi, Yukio ; Matsuno, Yoshihiro ; Tobinai, Kensei</creatorcontrib><description>The feasibility and efficacy of cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL (intermediate DLBCL/BL) have never been reported. The effects of adding rituximab to CODOX-M/IVAC have not been published either. Fifteen consecutive patients with a median age of 39 years were treated with modified CODOX-M/IVAC regimen (particularly, reducing the dose of methotrexate to 3 g/m
2
) with or without rituximab at our institution. Although all patients developed grade 4 neutropenia and grade 3/4 thrombocytopenia/anemia, 93% had febrile neutropenia, 60% showed transaminase elevation, and 40% had mucositis/stomatitis (all grade 3), there were no treatment-related deaths. Two of nine patients treated with rituximab developed biphasic late-onset neutropenia. Thirteen patients (87%) showed complete responses. The remaining two patients had refractory disease; one had presented with peritoneal dissemination and complex chromosomal abnormalities, while the other had double
IGH
–
MYC
and
IGH
–
BCL2
translocations. The estimated 5-year overall and progression-free survival were 87% each, with a median follow-up of 74 months. In conclusion, our modified CODOX-M/IVAC regimen is well tolerated and highly effective in Japanese adult patients with BL and intermediate DLBCL/BL, warranting a larger study for confirmation.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-010-0728-0</identifier><identifier>PMID: 21120644</identifier><language>eng</language><publisher>Japan: Springer Japan</publisher><subject><![CDATA[Adult ; Antibodies, Monoclonal, Murine-Derived - therapeutic use ; Antineoplastic Agents - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Burkitt Lymphoma - drug therapy ; Burkitt Lymphoma - pathology ; Cyclophosphamide - administration & dosage ; Cytarabine - administration & dosage ; Disease-Free Survival ; Doxorubicin - administration & dosage ; Etoposide - administration & dosage ; Female ; Hematologic and hematopoietic diseases ; Hematology ; Humans ; Ifosfamide - administration & dosage ; Infectious diseases ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphoma, B-Cell - drug therapy ; Lymphoma, B-Cell - pathology ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Methotrexate - administration & dosage ; Middle Aged ; Oncology ; Original Article ; Rituximab ; Treatment Outcome ; Vincristine - administration & dosage ; Viral diseases ; Young Adult]]></subject><ispartof>International journal of hematology, 2010-12, Vol.92 (5), p.732-743</ispartof><rights>The Japanese Society of Hematology 2010</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c453t-8dcb0167b6ebd067b0b2170de6fcfe4f9c2bc82f5ebd9d5a9d0a66aea7fc230f3</citedby><cites>FETCH-LOGICAL-c453t-8dcb0167b6ebd067b0b2170de6fcfe4f9c2bc82f5ebd9d5a9d0a66aea7fc230f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23751731$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21120644$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maruyama, Dai</creatorcontrib><creatorcontrib>Watanabe, Takashi</creatorcontrib><creatorcontrib>Maeshima, Akiko Miyagi</creatorcontrib><creatorcontrib>Nomoto, Junko</creatorcontrib><creatorcontrib>Taniguchi, Hirokazu</creatorcontrib><creatorcontrib>Azuma, Teruhisa</creatorcontrib><creatorcontrib>Mori, Masakazu</creatorcontrib><creatorcontrib>Munakata, Wataru</creatorcontrib><creatorcontrib>Kim, Sung-Won</creatorcontrib><creatorcontrib>Kobayashi, Yukio</creatorcontrib><creatorcontrib>Matsuno, Yoshihiro</creatorcontrib><creatorcontrib>Tobinai, Kensei</creatorcontrib><title>Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><addtitle>Int J Hematol</addtitle><description>The feasibility and efficacy of cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL (intermediate DLBCL/BL) have never been reported. The effects of adding rituximab to CODOX-M/IVAC have not been published either. Fifteen consecutive patients with a median age of 39 years were treated with modified CODOX-M/IVAC regimen (particularly, reducing the dose of methotrexate to 3 g/m
2
) with or without rituximab at our institution. Although all patients developed grade 4 neutropenia and grade 3/4 thrombocytopenia/anemia, 93% had febrile neutropenia, 60% showed transaminase elevation, and 40% had mucositis/stomatitis (all grade 3), there were no treatment-related deaths. Two of nine patients treated with rituximab developed biphasic late-onset neutropenia. Thirteen patients (87%) showed complete responses. The remaining two patients had refractory disease; one had presented with peritoneal dissemination and complex chromosomal abnormalities, while the other had double
IGH
–
MYC
and
IGH
–
BCL2
translocations. The estimated 5-year overall and progression-free survival were 87% each, with a median follow-up of 74 months. In conclusion, our modified CODOX-M/IVAC regimen is well tolerated and highly effective in Japanese adult patients with BL and intermediate DLBCL/BL, warranting a larger study for confirmation.</description><subject>Adult</subject><subject>Antibodies, Monoclonal, Murine-Derived - therapeutic use</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Burkitt Lymphoma - drug therapy</subject><subject>Burkitt Lymphoma - pathology</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Cytarabine - administration & dosage</subject><subject>Disease-Free Survival</subject><subject>Doxorubicin - administration & dosage</subject><subject>Etoposide - administration & dosage</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematology</subject><subject>Humans</subject><subject>Ifosfamide - administration & dosage</subject><subject>Infectious diseases</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymphoma, B-Cell - drug therapy</subject><subject>Lymphoma, B-Cell - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Methotrexate - administration & dosage</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Rituximab</subject><subject>Treatment Outcome</subject><subject>Vincristine - administration & dosage</subject><subject>Viral diseases</subject><subject>Young Adult</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNp1UktvEzEQXhCIhsIP4IIsJKREylJ73zk24VWUKhdA3Faz9rhx2bUX20uTf4-TDa2ExGlszfcYj78oesXoO0ZpeeFYwqo8pozGtEyqmD6OJqwq8jgty-xJNKGLJI_zktGz6Llzt5Sykmbls-gsYSyhRZZNHl1eG6GkQkH4nrem3xrXb6FTAufkt9LcKueVDhdhdsYOjeJKzwloQTr0W-Mt7sAjma427zc_4uvZhZLGyZMAetMbdzweGHzvwUIT5Mj06vvlakb8Fi30e3Kn_JYYe6xm8MQqP-xUBw1RmnyBHjQ6JCCG1pMevELt3UhaDvan8p60-y7M3gGZLtezo9uScGzb-8acDJq34Fx4LTRtGOnIlwh-sOiCkUfboVCH5zTo7xA1CauRQ3Buwd7gv4qjy_pF9FRC6_DlqZ5H3z5--Lr6HK83n65Wl-uYZ3nq40rwhrKibApsBA2VNkn4DoGF5BIzueBJw6tE5qG9EDksBIWiAIRS8iSlMj2P3oy6vTW_BnS-vjWD1cGyrlhRJMUiKwKIjSBujXMWZd3bsEe7rxmtD5mpx8zUITP1ITM1DZzXJ-GhCQu4Z_wNSQC8PQHAcWilBc2Ve8ClZc7KlAVcMuJcaOkbtA8T_t_9D3Xv4Jk</recordid><startdate>20101201</startdate><enddate>20101201</enddate><creator>Maruyama, Dai</creator><creator>Watanabe, Takashi</creator><creator>Maeshima, Akiko Miyagi</creator><creator>Nomoto, Junko</creator><creator>Taniguchi, Hirokazu</creator><creator>Azuma, Teruhisa</creator><creator>Mori, Masakazu</creator><creator>Munakata, Wataru</creator><creator>Kim, Sung-Won</creator><creator>Kobayashi, Yukio</creator><creator>Matsuno, Yoshihiro</creator><creator>Tobinai, Kensei</creator><general>Springer Japan</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20101201</creationdate><title>Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL</title><author>Maruyama, Dai ; Watanabe, Takashi ; Maeshima, Akiko Miyagi ; Nomoto, Junko ; Taniguchi, Hirokazu ; Azuma, Teruhisa ; Mori, Masakazu ; Munakata, Wataru ; Kim, Sung-Won ; Kobayashi, Yukio ; Matsuno, Yoshihiro ; Tobinai, Kensei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c453t-8dcb0167b6ebd067b0b2170de6fcfe4f9c2bc82f5ebd9d5a9d0a66aea7fc230f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Antibodies, Monoclonal, Murine-Derived - therapeutic use</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Burkitt Lymphoma - drug therapy</topic><topic>Burkitt Lymphoma - pathology</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Cytarabine - administration & dosage</topic><topic>Disease-Free Survival</topic><topic>Doxorubicin - administration & dosage</topic><topic>Etoposide - administration & dosage</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematology</topic><topic>Humans</topic><topic>Ifosfamide - administration & dosage</topic><topic>Infectious diseases</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymphoma, B-Cell - drug therapy</topic><topic>Lymphoma, B-Cell - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Methotrexate - administration & dosage</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Rituximab</topic><topic>Treatment Outcome</topic><topic>Vincristine - administration & dosage</topic><topic>Viral diseases</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maruyama, Dai</creatorcontrib><creatorcontrib>Watanabe, Takashi</creatorcontrib><creatorcontrib>Maeshima, Akiko Miyagi</creatorcontrib><creatorcontrib>Nomoto, Junko</creatorcontrib><creatorcontrib>Taniguchi, Hirokazu</creatorcontrib><creatorcontrib>Azuma, Teruhisa</creatorcontrib><creatorcontrib>Mori, Masakazu</creatorcontrib><creatorcontrib>Munakata, Wataru</creatorcontrib><creatorcontrib>Kim, Sung-Won</creatorcontrib><creatorcontrib>Kobayashi, Yukio</creatorcontrib><creatorcontrib>Matsuno, Yoshihiro</creatorcontrib><creatorcontrib>Tobinai, Kensei</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maruyama, Dai</au><au>Watanabe, Takashi</au><au>Maeshima, Akiko Miyagi</au><au>Nomoto, Junko</au><au>Taniguchi, Hirokazu</au><au>Azuma, Teruhisa</au><au>Mori, Masakazu</au><au>Munakata, Wataru</au><au>Kim, Sung-Won</au><au>Kobayashi, Yukio</au><au>Matsuno, Yoshihiro</au><au>Tobinai, Kensei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><addtitle>Int J Hematol</addtitle><date>2010-12-01</date><risdate>2010</risdate><volume>92</volume><issue>5</issue><spage>732</spage><epage>743</epage><pages>732-743</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>The feasibility and efficacy of cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL (intermediate DLBCL/BL) have never been reported. The effects of adding rituximab to CODOX-M/IVAC have not been published either. Fifteen consecutive patients with a median age of 39 years were treated with modified CODOX-M/IVAC regimen (particularly, reducing the dose of methotrexate to 3 g/m
2
) with or without rituximab at our institution. Although all patients developed grade 4 neutropenia and grade 3/4 thrombocytopenia/anemia, 93% had febrile neutropenia, 60% showed transaminase elevation, and 40% had mucositis/stomatitis (all grade 3), there were no treatment-related deaths. Two of nine patients treated with rituximab developed biphasic late-onset neutropenia. Thirteen patients (87%) showed complete responses. The remaining two patients had refractory disease; one had presented with peritoneal dissemination and complex chromosomal abnormalities, while the other had double
IGH
–
MYC
and
IGH
–
BCL2
translocations. The estimated 5-year overall and progression-free survival were 87% each, with a median follow-up of 74 months. In conclusion, our modified CODOX-M/IVAC regimen is well tolerated and highly effective in Japanese adult patients with BL and intermediate DLBCL/BL, warranting a larger study for confirmation.</abstract><cop>Japan</cop><pub>Springer Japan</pub><pmid>21120644</pmid><doi>10.1007/s12185-010-0728-0</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2010-12, Vol.92 (5), p.732-743 |
| issn | 0925-5710 1865-3774 |
| language | eng |
| recordid | cdi_proquest_journals_816626946 |
| source | Springer Link |
| subjects | Adult Antibodies, Monoclonal, Murine-Derived - therapeutic use Antineoplastic Agents - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Burkitt Lymphoma - drug therapy Burkitt Lymphoma - pathology Cyclophosphamide - administration & dosage Cytarabine - administration & dosage Disease-Free Survival Doxorubicin - administration & dosage Etoposide - administration & dosage Female Hematologic and hematopoietic diseases Hematology Humans Ifosfamide - administration & dosage Infectious diseases Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma, B-Cell - drug therapy Lymphoma, B-Cell - pathology Male Medical sciences Medicine Medicine & Public Health Methotrexate - administration & dosage Middle Aged Oncology Original Article Rituximab Treatment Outcome Vincristine - administration & dosage Viral diseases Young Adult |
| title | Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T16%3A09%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Modified%20cyclophosphamide,%20vincristine,%20doxorubicin,%20and%20methotrexate%20(CODOX-M)/ifosfamide,%20etoposide,%20and%20cytarabine%20(IVAC)%20therapy%20with%20or%20without%20rituximab%20in%20Japanese%20adult%20patients%20with%20Burkitt%20lymphoma%20(BL)%20and%20B%20cell%20lymphoma,%20unclassifiable,%20with%20features%20intermediate%20between%20diffuse%20large%20B%20cell%20lymphoma%20and%20BL&rft.jtitle=International%20journal%20of%20hematology&rft.au=Maruyama,%20Dai&rft.date=2010-12-01&rft.volume=92&rft.issue=5&rft.spage=732&rft.epage=743&rft.pages=732-743&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-010-0728-0&rft_dat=%3Cproquest_cross%3E2207773641%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c453t-8dcb0167b6ebd067b0b2170de6fcfe4f9c2bc82f5ebd9d5a9d0a66aea7fc230f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=816626946&rft_id=info:pmid/21120644&rfr_iscdi=true |